Description:

Flibanserin is a novel, non-hormonal drug that has been studied in clinical trials for the treatment

of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA

is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or

chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin

corrects an imbalance of levels of these neurotransmitters by increasing dopamine and

norepinephrine and decreasing serotonin. In clinical studies, flibanserin was evaluated for its

ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire

and decrease the associated distress women feel from its loss.

Adrug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive

sexual desire disorder (HSDD).

Application:

A new drug designed to boost sexual desire in women is controversial for some and eagerly

awaited by others, but it's hit a potentially serious snag. The drug didn't boost women's desire any

more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical

trial results on its website today in advance of a committee meeting on Friday, when a panel of

experts will vote whether or not to recommend approval of the drug called flibanserin. (The FDA

usually follows the recommendations of its expert panels). Although there was a slight increase in

the number of sexually satisfying events flibanserin users had each month, the FDA staff who

reviewed the results said the so-called response rate isn't 'particularly compelling'.

It's called the 'Female Viagra', a tiny tablet that could have a huge impact on treating female

sexual dysfunction. If it's approved, it would become the first drug of its kind on the market.

Skype&Whatsapp:86 13690838732

Email: ycsales12@ycphar.com